TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Amrutanjan Health Care Limited
AMRUTANJANSmall CapNSEBSE
Biotechnology & Drugs · Biotechnology & Drugs
₹509.35down 4.90down 0.95 percentas of 31 Aug 2026
Book value ₹126.70Div yield 1.47%
Key metrics
- Market Cap
- 1,491.63 ₹ cr
- P/E
- 25.67 x
- P/B
- 4.02 x
- ROE
- 15.64%
- ROCE
- 15.81%
- Debt to Equity
- 0.00 x
- Net Margin
- 11.53%
- Dividend Yield
- 1.47%
- Revenue Growth (YoY)
- 9.48%
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- ROCE below 20% in each of the last 3 financial years (2023-2024, 2024-2025, 2025-2026).
- Revenue grew year-on-year in each of the last 3 years.
- Net margin grew year-on-year in each of the last 3 years.
- Promoter holding 46.5% (pledge data not available).
- Debt-to-equity 0.00 — below the Biotechnology & Drugs median of 0.13.
AMRUTANJAN
₹509.35down 0.95 percent
EOD Synced: 31 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatStable Return Franchise
15.81%ROCE
ROE: 15.64%·P/B: 4.02x
2. Forensic Health & SolvencyPiotroski 5/9 · Adequate Health
5/9Piotroski Score
Altman: 8.1 (Safe Zone)
3. Valuation & DCF SpreadFairly Valued
₹526DCF Fair Value
CMP: ₹509.4
4. Ownership & GovernanceClean Promoter Holding
46.52%Promoter Stake
Pledged: 0.0%·Inst: 8.26%
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #19 of 35 in Biotechnology & DrugsQVGM 50/100
Quality (Q)66
ROE, ROCE, Margins & Cash Conversion
Value (V)60
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)44
3Y Sales & EPS Compounded Growth
Momentum (M)23
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #19 of 35 in Biotechnology & Drugs
Valuation
Moderate60/100
P/E Ratio:25.67x
P/B Ratio:4.02x
Dividend Yield:1.47%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Moderate44/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Moderate66/100
ROE:15.6%
ROCE:15.8%
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Moderate56/100
Piotroski F-Score:5/9
Altman Z-Score:8.09
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Weak23/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹488.25
From 52W High-33.71%
52-Week High₹768.35
Valuation MultiplesCash Flow & Yield
PEG Ratio1.44
Earnings Yield4.38%
Price / FCF—
FCF Yield-1.28%
Payout Ratio33.62%
Net-Net Ratio10.26
Solvency & SafetyPiotroski & Altman
Piotroski F-Score5/9
Altman Z-Score8.09
Graham Number₹252.19
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▲ +0.27%
DII Stake:▼ 1.20%
OPM Margin:▲ +0.60%
Net Margin:▲ +0.28%
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | ▼ 31.25% | ▲ +9.48% | 11.23% | 9.80% | 8.59% |
| Net Profit Growth | ▼ 73.01% | ▼ 47.41% | 13.95% | 13.29% | -1.09% |
| EPS Growth | ▼ 73.66% | ▼ 29.97% | 26.55% | 17.88% | 1.30% |
Intrinsic Valuation Models & DCF Sensitivity
Institutional DCF & Intrinsic Valuation Studio — AMRUTANJAN
2-Stage Discounted Cash Flow, Reverse DCF Implied Growth, and Benjamin Graham & Peter Lynch valuation benchmarks.
DCF Intrinsic Fair Value
₹541.9
Verdict:Fairly Valued (+6.4%)
Benjamin Graham Number
₹253.6
-50.2% vs CMPPeter Lynch Fair Value
₹398.9
-21.7% vs CMPReverse DCF Implied Growth
6.4% CAGR
Realistic Market ExpectationsValuation Spectrum PositioningCMP: ₹509.4
₹0 (Distress)CMP: ₹509DCF: ₹542Graham: ₹254
Scenario Calibration & Sensitivity Levers
Tune Discount Rate (WACC), 5-Year Growth, and Terminal Value to model bear, base, and bull cases.
Discount Rate (WACC)11.5%
Cost of Capital Hurdle
5-Year FCF Growth CAGR7.3%
Assumed stage-1 cash flow expansionTerminal Growth Rate4.5%
Long-term perpetual GDP growth rate5-Year Projected Cash Flow Schedule (₹ Cr)
| Projection Period | Growth Rate | Projected FCF | Discount Factor | Present Value |
|---|---|---|---|---|
| Year 1 | 7.3% | ₹98 | 0.8969 | ₹88 |
| Year 2 | 7.3% | ₹105 | 0.8044 | ₹84 |
| Year 3 | 7.3% | ₹112 | 0.7214 | ₹81 |
| Year 4 | 7.3% | ₹121 | 0.6470 | ₹78 |
| Year 5 | 7.3% | ₹129 | 0.5803 | ₹75 |
2D Sensitivity Matrix (WACC vs Terminal Growth Rate)
Click any cell to apply WACC & terminal growth scenario. Values in ₹ / share.| WACC \ g(Terminal) | 3.0% | 4.0% | 4.5% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | ₹569 +12% | ₹642 +26% | ₹688 +35% | ₹744 +46% | ₹897 +76% |
| 11.0% | ₹498 -2% | ₹551 +8% | ₹583 +14% | ₹621 +22% | ₹719 +41% |
| 11.5% | ₹469 -8% | ₹514 +1% | ₹542 +6% | ₹574 +13% | ₹655 +29% |
| 12.0% | ₹443 -13% | ₹483 -5% | ₹506 -1% | ₹533 +5% | ₹601 +18% |
| 13.0% | ₹399 -22% | ₹430 -16% | ₹447 -12% | ₹468 -8% | ₹517 +1% |
Discounted cash flow (DCF) and valuation models are quantitative projections based on user-supplied assumptions — not a forecast, not a guarantee of future performance, and not SEBI-registered investment advice. Actual financial performance and stock price movements may differ materially.
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E25.67current
ReportedComputed, approximate
P/B4.02current
ReportedComputed, approximate
The dashed line is computed from historical close price divided by the most recently reported annual EPS or book value — not IndianAPI's own figure, which only ever gives a single current reading with no history behind it. Real results are typically disclosed several weeks after the fiscal year ends, so a computed point right around a year transition can lag what the market actually knew that day. The solid line is the real reported figure.
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | 25.67 | 4.02 |
Analyst Consensus, Price Targets & Forecasts
Analyst Ratings
No analyst consensus data available for this company.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
Balanced risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:30.36%
Price Target
No analyst target price estimates available for this company.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2027E6 Analysts
Mean Estimate
₹6.09
Low:—
High:—
FY2027E6 Analysts
Mean Estimate
₹6.41
Low:—
High:—
FY2027E6 Analysts
Mean Estimate
₹6.73
Low:—
High:—
FY2027E6 Analysts
Mean Estimate
₹7.06
Low:—
High:—
FY2028E6 Analysts
Mean Estimate
₹6.99
Low:—
High:—
FY2028E6 Analysts
Mean Estimate
₹7.36
Low:—
High:—
FY2028E6 Analysts
Mean Estimate
₹7.73
Low:—
High:—
FY2028E6 Analysts
Mean Estimate
₹8.10
Low:—
High:—
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2027 Forecast | ₹6.09 | — | — | 6 |
| FY2027 Forecast | ₹6.41 | — | — | 6 |
| FY2027 Forecast | ₹6.73 | — | — | 6 |
| FY2027 Forecast | ₹7.06 | — | — | 6 |
| FY2028 Forecast | ₹6.99 | — | — | 6 |
| FY2028 Forecast | ₹7.36 | — | — | 6 |
| FY2028 Forecast | ₹7.73 | — | — | 6 |
| FY2028 Forecast | ₹8.10 | — | — | 6 |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
Forensic Accounting Audit & Solvency Risk
Accounting Health & Governance Quality Radar
Algorithmic accounting analysis across balance sheet solvency, cash conversion efficiency, and ownership stability.
Clean Governance & Solvency
Financial Strengths & Catalysts
2 Factors- •Company is virtually debt-free with a Debt-to-Equity ratio of 0.00x.
- •Company has reduced borrowings by 14.4% over the last fiscal year.
Risk Factors & Watchouts
0 WatchoutsClean profile: No major debt, leverage, or working capital red flags detected.
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score5 / 9
● Moderate (Neutral)
Altman Z-Score8.09
● Safe Zone
Negligible risk of financial distress over the next 2 years.
Beneish M-Score-2.46
● Low Risk (Clean Accounting)
Cash flows closely match reported earnings with conservative accruals.
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
Accounting Flow:
Wall Street Cash Flow & Free Cash Flow (FCF) Cascade
FY26 (2025-2026)3-Stage institutional flow from reported earnings to owner Free Cash Flow and capital allocation
FCF Conversion Rate (FCF / PAT)
-32.9%Low Cash Conversion
Measures how much reported accounting profit turns into real liquid cash.
Free Cash Flow Margin
-3.8%of Gross Revenue
Liquid cash retained per ₹100 of top-line revenue generated.
CapEx Reinvestment Rate
152.9%of Operating Cash
Portion of operating cash reinvested in future capacity and maintenance.
Reported Net Profit (PAT)₹58 CrInflow
58
+ D&A Non-Cash Charge₹6 CrAdd-back
6
Working Capital Adjustment-₹28 Cr- Tied Up
28
= Operating Cash Flow (CFO)₹36 CrOperating Cash
36
- Capital Expenditures (CapEx)-₹55 CrReinvestment
55
= Free Cash Flow (FCF)-₹19 CrFree Cash Flow
19
- Dividends & Debt Repayment-₹13 CrCapital Return
13
= Net Change in Cash-₹32 CrNet Balance
32
Multi-Year Historical FCF vs Reported PAT Trajectory:
Free Cash Flow (FCF) Reported Net Profit (PAT)
| Metric | 2018-201931 Mar 2019 | 2019-202031 Mar 2020 | 2020-202131 Mar 2021 | 2021-202231 Mar 2022 | 2022-202331 Mar 2023 | 2023-202431 Mar 2024 | 2024-202531 Mar 2025 | 2025-202631 Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹253.23 | ₹261.48 | ₹332.84 | ₹405.84 | ₹379.64 | ₹421.23 | ₹451.82 | ₹502.55 |
| Operating profit | ₹28.12 | ₹26.35 | ₹71.08 | ₹75.68 | ₹39.39 | ₹45.99 | ₹51.67 | ₹60.51 |
| OPM | 11.10% | 10.08% | 21.36% | 18.65% | 10.38% | 10.92% | 11.44% | 12.04% |
| Net profit | ₹24.51 | ₹25.08 | ₹61.19 | ₹67.19 | ₹39.83 | ₹44.97 | ₹50.83 | ₹57.92 |
| EPS | 8.61 | 8.58 | 20.91 | 22.98 | 13.62 | 15.65 | 17.63 | 22.31 |
| Net margin | 9.68% | 9.59% | 18.38% | 16.56% | 10.49% | 10.68% | 11.25% | 11.53% |
| ROE | 16.82% | 15.73% | 28.39% | 25.34% | 13.70% | 15.59% | 15.56% | 15.64% |
| ROCE | 18.56% | 15.85% | 31.99% | 27.78% | 13.17% | 15.49% | 15.34% | 15.81% |
| Debt / equity | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
Compounded growth (CAGR)
| Metric | 1Y | 3Y | 5Y |
|---|---|---|---|
| Revenue | 11.23% | 9.80% | 8.59% |
| Net profit | 13.95% | 13.29% | -1.09% |
| EPS | 26.55% | 17.88% | 1.30% |
Each column only appears when 8 real reported years actually support it — never extrapolated from fewer.
Balance sheet
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₹187.61 | ₹205.35 | ₹274.27 | ₹349.87 | ₹362.09 | ₹366.87 | ₹421.39 | ₹508.89 |
| Total liabilities | ₹41.88 | ₹45.92 | ₹58.71 | ₹84.74 | ₹71.32 | ₹78.38 | ₹94.77 | ₹138.66 |
| Total equity | ₹145.74 | ₹159.43 | ₹215.56 | ₹265.12 | ₹290.77 | ₹288.49 | ₹326.61 | ₹370.23 |
| Total debt | ₹0.00 | ₹1.69 | ₹1.34 | ₹0.88 | ₹0.91 | ₹1.73 | ₹2.08 | ₹1.78 |
| Cash | ₹14.59 | ₹1.22 | ₹2.91 | ₹2.19 | ₹4.90 | ₹3.71 | ₹10.16 | — |
| Current assets | ₹139.62 | ₹125.82 | ₹222.90 | ₹274.65 | ₹259.54 | ₹295.68 | ₹290.67 | ₹291.65 |
| Current liabilities | ₹36.12 | ₹39.06 | ₹52.10 | ₹77.47 | ₹63.01 | ₹69.92 | ₹84.58 | ₹126.18 |
| Inventory | ₹17.56 | ₹25.39 | ₹19.36 | ₹27.18 | ₹29.95 | ₹30.34 | ₹29.27 | ₹37.35 |
| Receivables | ₹32.93 | ₹26.46 | ₹17.66 | ₹38.26 | ₹36.53 | ₹52.32 | ₹60.39 | ₹60.64 |
| Payables | ₹29.87 | ₹31.34 | ₹40.67 | ₹60.45 | ₹47.44 | ₹55.86 | ₹69.04 | ₹70.90 |
| Net PP&E | ₹25.28 | ₹25.57 | ₹23.32 | ₹43.47 | ₹47.55 | ₹49.54 | ₹63.93 | ₹155.29 |
| Retained earnings | ₹142.81 | ₹156.50 | ₹213.61 | ₹266.70 | ₹292.31 | ₹287.21 | ₹324.78 | ₹367.34 |
Cash flow
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | ₹21.17 | ₹18.18 | ₹89.76 | ₹52.20 | ₹20.18 | ₹27.91 | ₹50.90 | ₹35.97 |
| Capital expenditure | ₹-2.04 | ₹-2.54 | ₹-1.96 | ₹-23.46 | ₹-8.93 | ₹-6.72 | ₹-35.55 | ₹-55.00 |
| Free cash flow | ₹19.13 | ₹15.64 | ₹87.80 | ₹28.74 | ₹11.25 | ₹21.19 | ₹15.35 | ₹-19.03 |
| OCF / net profit | 0.86 | 0.72 | 1.47 | 0.78 | 0.51 | 0.62 | 1.00 | 0.62 |
| FCF / Capex intensity | 0.81 | 0.97 | 0.59 | 5.78 | 2.35 | 1.60 | 7.87 | 10.94 |
Income statement detail
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | ₹132.47 | ₹142.39 | ₹190.90 | ₹222.72 | ₹194.60 | ₹205.56 | ₹225.09 | ₹258.19 |
| Cost of revenue | ₹120.76 | ₹119.09 | ₹141.94 | ₹183.13 | ₹185.04 | ₹215.67 | ₹226.72 | ₹244.36 |
| EBITDA | ₹31.28 | ₹30.71 | ₹74.75 | ₹79.48 | ₹44.60 | ₹52.05 | ₹58.20 | ₹66.83 |
| Income before tax | ₹35.17 | ₹34.45 | ₹81.90 | ₹90.58 | ₹53.65 | ₹61.95 | ₹69.13 | ₹77.89 |
| Interest expense | — | — | — | — | — | — | — | ₹0.20 |
| Tax expense | ₹10.17 | ₹9.37 | ₹20.71 | ₹23.39 | ₹13.81 | ₹16.97 | ₹18.30 | ₹19.97 |
| D&A | ₹3.16 | ₹4.36 | ₹3.67 | ₹3.80 | ₹5.21 | ₹6.06 | ₹6.53 | ₹6.32 |
| EBITDA margin | 12.35% | 11.74% | 22.46% | 19.58% | 11.75% | 12.36% | 12.88% | 13.30% |
Financial ratios
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.87 | 3.22 | 4.28 | 3.55 | 4.12 | 4.23 | 3.44 | 2.31 |
| Quick ratio | 3.38 | 2.57 | 3.91 | 3.19 | 3.64 | 3.79 | 3.09 | 2.02 |
| Interest coverage | — | — | — | — | — | — | — | 302.55 |
| Inventory days | 53.08 | 77.82 | 49.78 | 54.17 | 59.08 | 51.35 | 47.12 | 55.79 |
| Receivable days | 47.46 | 36.94 | 19.37 | 34.41 | 35.12 | 45.34 | 48.79 | 44.04 |
| Payable days | 90.28 | 96.05 | 104.58 | 120.48 | 93.58 | 94.54 | 111.15 | 105.90 |
| Cash conversion cycle | 10.26 | 18.70 | -35.43 | -31.90 | 0.62 | 2.15 | -15.24 | -6.07 |
| Working capital days | — | — | — | — | — | — | — | — |
| Fixed asset turnover | 10.02 | 10.23 | 14.27 | 9.34 | 7.98 | 8.50 | 7.07 | 3.24 |
| ROA | 13.06% | 12.21% | 22.31% | 19.20% | 11.00% | 12.26% | 12.06% | 11.38% |
| ROIC | 15.24% | 12.00% | 24.82% | 21.28% | 10.20% | 11.65% | 11.93% | — |
| Gross margin | 52.31% | 54.46% | 57.35% | 54.88% | 51.26% | 48.80% | 49.82% | 51.38% |
DuPont 3-Stage ROE Factor Decomposition
Deconstructing Return on Equity into Profitability, Asset Efficiency, and Financial Leverage
Balanced Return EngineFY2025-2026
Net marginProfitability
11.53%
Net Profit generated per ₹100 of revenue (Profitability)
×
Asset turnoverEfficiency
0.99
Revenue generated per ₹1 of total assets (Capital Efficiency)
×
Equity multiplierLeverage
1.37
Total assets supported per ₹1 of shareholder equity (Leverage)
=
Implied DuPont ROEFinal Output
15.64%
Reported: 15.64%
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 11 Sept 2026 | dividend | 290% |
| 07 Feb 2026 | dividend | 100% | |
| 2025 | 18 Nov 2025 | dividend | 100% |
| 16 Sept 2025 | dividend | 260% | |
| 18 Feb 2025 | dividend | 100% | |
| 2024 | 22 Nov 2024 | dividend | 100% |
| 17 Sept 2024 | dividend | 260% | |
| 20 Feb 2024 | dividend | 100% | |
| 2023 | 23 Nov 2023 | dividend | 100% |
| 14 Sept 2023 | dividend | 260% | |
| 24 Feb 2023 | dividend | 100% | |
| 2022 | 15 Nov 2022 | dividend | 100% |
| 16 Sept 2022 | dividend | 260% | |
| 21 Feb 2022 | dividend | 100% | |
| 2021 | 17 Nov 2021 | dividend | 100% |
| 16 Sept 2021 | dividend | 260% | |
| 19 Feb 2021 | dividend | 80% | |
| 2020 | 20 Nov 2020 | dividend | 80% |
| 21 Feb 2020 | dividend | 155% | |
| 2019 | 18 Nov 2019 | dividend | 55% |
| 19 Sept 2019 | dividend | 105% | |
| 19 Sept 2019 | dividend | 105% | |
| 21 Feb 2019 | dividend | 55% | |
| 2018 | 13 Nov 2018 | dividend | 55% |
| 11 Sept 2018 | dividend | 85% | |
| 16 Apr 2018 | split | 1:2 | |
| 23 Feb 2018 | dividend | 55% | |
| 2017 | 17 Nov 2017 | dividend | 55% |
| 14 Sept 2017 | dividend | 82% | |
| 17 Feb 2017 | dividend | 55% | |
| 2016 | 18 Nov 2016 | dividend | 55% |
| 21 Mar 2016 | dividend | 132% | |
| 19 Feb 2016 | dividend | 60% | |
| 2015 | 12 Sept 2015 | dividend | 120% |
| 17 Feb 2015 | dividend | 55% | |
| 2014 | 19 Sept 2014 | dividend | 110% |
| 19 Feb 2014 | dividend | 50% | |
| 2013 | 06 Aug 2013 | dividend | 100% |
| 22 Feb 2013 | dividend | 50% | |
| 2012 | 29 Oct 2012 | split | 2:10 |
| 24 Sept 2012 | dividend | 100% | |
| 24 Feb 2012 | dividend | 50% | |
| 2011 | 14 Sept 2011 | dividend | 100% |
| 22 Feb 2011 | dividend | 50% | |
| 2010 | 17 Aug 2010 | dividend | 100% |
| 10 Feb 2010 | dividend | 50% | |
| 2009 | 18 Sept 2009 | dividend | 120% |
| 05 Feb 2009 | dividend | 50% | |
| 2008 | 10 Sept 2008 | dividend | 30% |
| 29 Jul 2008 | dividend | 400% | |
| 06 Feb 2008 | dividend | 40% | |
| 2007 | 07 Aug 2007 | dividend | 20% |
| 25 Jan 2007 | dividend | 40% | |
| 2006 | 05 Jul 2006 | dividend | 27% |
| 15 Feb 2006 | dividend | 13% |
Dividend Intelligence & Capital Return History
Historical cash payout track record across 17 dividend distributions
Latest Year DPS:₹3.90
Yield on CMP:0.77%
3Y Dividend CAGR:-5.4%
Annual Dividend Payout Progression (Per Share)Total Cumulative DPS: ₹26.70
₹3.9
2026
₹4.6
2025
₹4.6
2024
₹4.6
2023
₹4.6
2022
₹4.4
2021
| Ex-Date | Amount (Per Share) | Dividend Type |
|---|---|---|
| 11 Sept 2026 | ₹2.90 | Final |
| 06 Feb 2026 | ₹1.00 | Interim |
| 18 Nov 2025 | ₹1.00 | Interim |
| 16 Sept 2025 | ₹2.60 | Final |
| 18 Feb 2025 | ₹1.00 | Interim |
| 22 Nov 2024 | ₹1.00 | Interim |
| 13 Sept 2024 | ₹2.60 | Final |
| 20 Feb 2024 | ₹1.00 | Interim |
| 23 Nov 2023 | ₹1.00 | Interim |
| 14 Sept 2023 | ₹2.60 | Final |
| 24 Feb 2023 | ₹1.00 | Interim |
| 14 Nov 2022 | ₹1.00 | Interim |
| 14 Sept 2022 | ₹2.60 | Final |
| 18 Feb 2022 | ₹1.00 | Interim |
| 16 Nov 2021 | ₹1.00 | Interim |
| 15 Sept 2021 | ₹2.60 | Final |
| 17 Feb 2021 | ₹0.80 | Interim |
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
Biotechnology & DrugsCompare Peers in Studio
Market Cap1,491.63 ₹ cr
Beats 78% of 9 industry peers · median 821.74 ₹ cr
P/E25.67 x
Beats 57% of 7 industry peers · median 21.47 x
P/B4.02 x
Beats 100% of 8 industry peers · median 1.66 x
ROE15.64%
Beats 100% of 8 industry peers · median 7.85%
ROCE15.81%
Beats 63% of 8 industry peers · median 5.30%
Debt to Equity0.00 x
Beats 25% of 8 industry peers · median 0.13 x
Net Margin11.53%
Beats 63% of 8 industry peers · median 3.95%
Dividend Yield1.47%
Beats 50% of 6 industry peers · median 1.19%
Revenue Growth (YoY)9.48%
Beats 38% of 8 industry peers · median 18.25%
| Company | Market Cap ▼ | P/E | P/B |
|---|---|---|---|
AstraZeneca Pharma India LimitedASTRAZEN | ₹17,813.30 | — | — |
Alembic LimitedALEMBICLTD | ₹2,540.32 | 8.09 | 1.05 |
Bajaj Healthcare LimitedBAJAJHCARE | ₹1,129.36 | 47.93 | 2.03 |
| ₹829.17 | 26.55 | 3.67 | |
Anuh Pharma LimitedANUHPHR | ₹821.74 | 20.41 | 2.38 |
Peers are chosen strictly by industry classification. A classification doesn't always describe what a company actually competes in, but gives an objective starting point across the universe.
Regulatory Filings & Market Intelligence
Corporate Document & Filings Vault
No statutory exchange announcements or PDF filings have been recorded for AMRUTANJAN yet.
News
- IndianAPIDixon Technologies, Karnataka Bank among 7 key stocks to trade Ex-dividend today, 16 September 2025
Dividend Stocks 2025: Dixon Technologies, Karnataka Bank, Amrutanjan Health Care, J. Kumar Infraprojects, Sigachi Industries, Skipper and Aarti Surfactants are among 7 key companies to trade ex dividend today, 16 September 2025
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.